Related Experiment Video
Updated: Jun 21, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Travoprost in the management of open-angle glaucoma and ocular hypertension
Philippe Denis1, David Covert, Anthony Realini
1Service d’ Ophtalmologie, Pavillon C, Hôpital Edouard Herriot, 5, place d’ Arsonval, 69437 LYON cédex 03, France. philippe.denis@chu-lyon.fr
Abstract:
Travoprost is a member of the prostaglandin analogue class of intraocular pressure (IOP)-lowering drugs used to treat ocular hypertension and glaucoma. Like other prostaglandin analogues, travoprost lowers IOP by enhancing the egress of aqueous humor through both the uveoscleral and trabecular outflow channels. This review summarizes the published data regarding the safety and efficacy of travoprost. Travoprost provides statistically significant and clinically relevant reductions in mean IOP, of the order of 6.5-9.0 mmHg in most studies. In addition, travoprost provides consistent diurnal IOP control, with statistically significant IOP reductions persisting up to 84 hours post-dose. Travoprost has a highly favorable safety profile; most adverse events are cosmetic in nature (such as iris hyperpigmentation and eyelash growth), although more serious adverse events (such as iritis and macular edema) have been associated with travoprost and the other prostaglandin drugs. In some markets, travoprost is available in a fixed combination with timolol; clinical studies have demonstrated that the fixed combination - dosed once daily - lowers IOP by 7-11.5 mmHg. In conclusion, travoprost provides safe and effective reduction of IOP, with convenient once-daily dosing, supporting its role as primary monotherapy.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Ophthalmic Drug Delivery Systems
Direct-Acting Cholinergic Agonists: Therapeutic Uses